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ABSTRACT  
Objective: Osteoarthritis (OA) is a chronic disease caused by inflammation of the tissue and bony structure of the joint, which affects more than 235 
million people worldwide. Due to the adverse effects caused by the long-term use of standard treatment of OA, the attempt to find natural remedies 
to treat chronic diseases continues to rise. Curcuma longa is known to have anti-inflammatory effects, which may impact the pathophysiology of OA. 
While many randomized controlled trials show the efficacy of Curcuma longa extract in the treatment of OA, there has been no comprehensive 
review of this evidence. 
Methods: We systematically searched PubMed, Cochrane, Scopus, ProQuest, EBSCOhost, and ScienceDirect for randomized controlled trials that 
evaluated Curcuma longa extract (CE extract) vs. control (placebo or other therapy). Three trials were identified. Data were then extracted from the 
studies and summarized descriptively. 
Results: Across all trials, Curcuma longa therapy was proven to reduce Visual Analog Scale (VAS) and Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) scores significantly compared to the control group. Adverse effects were less likely to appear in patients treated with 
Curcuma longa extract compared to other groups. 
Conclusion: CL extract is beneficial as an alternative medication for OA treatment, shown by the reduced scores of the Visual Analog Scale (VAS) 
and WOMAC in all studies we reviewed.  
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INTRODUCTION  
Osteoarthritis (OA), one of the most common types of arthritis, is a 
chronic disease caused by inflammation of the tissue and bony 
structures of the joint. This condition worsens over time and may 
lead to the decreased thickness of the articular cartilage, narrowing 
of the joint space, increased density of the subchondral bone, 
formulation of osteophytes, and thickening of the synovial 
membrane, hence resulting in disability and the complete 
breakdown of cartilage [1, 2]. 
In the United States, OA affects more than 27 million adults and is 
currently the leading cause of chronic disability [3]. The World 
Health Organization’s Global Burden of Disease Study identifies OA 
as a major contributor to disability, which affects more than 235 
million people worldwide [4]. In developing countries, including 
Asia, people tend to have longer life expectancies, and it is 
predicted that OA will double in the next two decades, from 6.8% 
in 2008 to 16.2% in 2040 [5]. In Indonesia, it is estimated that OA 
will occur in 15.5% of men and 12.7% of women in the later stages 
of life [6]. 
The consequence of OA is notable due to its common presentation in 
earlier age groups, particularly in younger women with obesity. 
Furthermore, the economic cost of OA is high due to its lengthy 
treatment and patients’ reduced productivity. Individuals who 
experience limitations in their daily activities due to OA may lose 
their jobs, thus affecting their families [3]. 
Various options for OA treatments include pharmacological, non-
pharmacological, and surgical interventions. Pharmacological agents 
are the most frequently used option, which include acetaminophen, 
NSAIDs (naproxen, salicylates, ibuprofen, selective COX2 inhibitor 
(celecoxib)), glucosamine (GS), chondroitin sulfate, capsaicin, intra-
articular injections of hyaluronic acid, and steroids. The side effects 
of these analgesics vary from mild gastritis to gastric ulcers, 
bleeding, and perforation [7]. Moreover, prolonged use of NSAIDs 
has been reported to produce side effects that affect the kidneys and 
gastrointestinal system. Similarly, therapy using steroids is known 
to slow the repair process and worsen OA [8]. 
Thus, the identification of a different way to treat OA with fewer side 
effects is becoming more important. Medicinal plants have been long 
known to be an important source of bioactive compounds, which 
produce fewer side effects and can deliver a very high therapeutic 
index. Worldwide, herbal agents are being studied for their scientific 
parameters and ability to treat OA [8]. Curcuma longa, commonly 
known as turmeric, contains curcumin, d
Furthermore, curcumin also exhibits antioxidant properties in the 
inhibition of nitric oxide synthase (NOS) production [9]. A recent 
study has shown that curcumin affects inhibition in collagenase and 
es-curcumin and des-
metoxycurcumin that is known to have potent antioxidant, anti-
inflammation, antimicrobial, and anti-carcinogenic effects. This plant 
has been widely used in East Asia for more than 100 y. Curcumin 
works both directly and indirectly through genomic activity 
provided by pro-inflammatory (PI) cytokines [8]. An animal study 
conducted by Pinsornsak et al. [7] reported that curcumin works by 
down-regulating the activation of NF-kB, which inhibits 
inflammatory mediators that include cyclooxygenase-2 (COX-2), 5-
Lipoxygenase (LOX), adhesive molecules, and MMPs. Also, curcumin 
has been shown to suppress many pro-inflammatory (PI) cytokines, 
such as interleukin (IL)-1, IL-8, and nitric oxide synthase (NOS) [9, 
10]. A study conducted by Kuptniratsaikul et al. [9] found that 
curcumin also inhibited the secretion of collagenase, etalase, and 
hyaluronidase. Moreover, curcumin was found to inhibit the 
activation of free radical activated transcription factors, such as AP-
1 and NF-kB, and reduced PI cytokines, such as tumor necrosis 
factor alpha, interleukin-1 beta, and interleukin-8.  
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stromelysin expression at micromolar concentrations, which 
suggests its therapeutic potential for the treatment of arthritis [11]. 
This outcome is also supported by a clinical trial conducted by 
Srivastava et al.[8] that Curcuma longa showed a significant 
improvement in patients with OA by increasing their quality of life 
and decreasing their pain [8].  
The evidence noted above proves the value of Curcuma longa as a 
potential therapy for OA. The objective of this research is to provide 
a systematic review of the current evidence regarding the clinical 
efficacy of Curcuma longa in treating people with OA. 
MATERIALS AND METHODS  
Eligibility criteria  
This study reviews evidence from randomized controlled trials (RCT) 
that assess the efficacy and safety of orally-administered Curcuma longa 
extract (CL extract) in the treatment of OA patients. Improvements in the 
VAS and the WOMAC Scale were used to establish the clinical relevance 
of existing statistical tests, used to compare scores between the use of 
placebo and standard treatment of OA with CL extract, based on the 
reviewed articles. Patients reviewed in this systematic review were of 
any age, gender, race, and length of follow-up. 
Search strategy  
To answer our objective, we conducted a systematic review of the 
literature according to the PRISMA[12] guidelines. A comprehensive 
search was performed in September 2018 in which we searched the 
PubMed, Cochrane Library, Scopus, EBSCOhost, ScienceDirect, and 
ProQuest databases, using keywords related to OA and Curcuma 
longa without language restrictions. The following keywords were 
used in searches of all the databases mentioned above: “Curcuma 
longa AND osteoarthritis.” 
Selection of studies 
The criteria for inclusion and exclusion were determined before the 
searches. We included RCTs that studied OA patients with treatment 
using CL extract compare to the control group, which use standard 
pharmacological treatment of OA (such as diclofenac, glucosamine, 
and ibuprofen) and placebo. Studies with relevant titles were then 
collected and screened. Studies found in more than one database 
were removed. Full-paper manuscripts were then studied, and those 
that were irrelevant were excluded. Three studies were included in 
the systematic review. 
Data extraction 
Selected studies were further studied, and relevant information 
was extracted. Relevant information included the following: (1) 
study design, (2) patient characteristics, (3) intervention 
regimens, (4) controls (placebo and standard treatment) 
regimens, (5) safety and adverse effect from the treatment, and (6) 
method used to analyze the results. The primary outcome of 
interest was the treatment efficacy of orally-administered CL 
extract, classified as improvements of the value of VAS and 
WOMAC, compared to the baseline. Secondary outcomes in this 
review included adverse events from the therapy. 
Risk of bias assessment  
For all the selected studies, a risk of bias assessment was conducted 
with The Cochrane Risk of Bias Tool [13], which allows assessors to 
judge the selected studies based on seven domains of bias. Any 
disagreements in the judgment of risk of bias were discussed and 
resolved between all authors before a final consensus was reached. 
Full details on our risk of bias assessment are described in the 
Results section and the Discussion.  
RESULTS  
Search results  
The results of the search are shown in fig. 1. In the initial search, a 
total of 14 studies were acknowledged, of which ten were duplicates. 
However, after reading the full articles of the remaining studies, one 
study was excluded based on previously determined exclusion 
criteria. The remaining three studies were then selected as the final 
studies [7, 8, 10]. 
Study characteristics 
Table 1 shows information regarding the patients’ characteristics, 
inclusion, and exclusion criteria, regimes, control (placebo), and 
outcome measures from the three studies. 
 
 
Fig. 1: Search results 
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Table 1: Summary of experimental designs of two studies 




Age: >40 y (Mean age 56.8, 56.3, 56.8, 58.2 in control, NR-INF-
02, GS, and NRF-INF-02 (CL extract)+GS groups respectively) 
Inclusion Criteria: Primary knee OA patients above 40 y 
Exclusion criteria: concurrent medical or arthritic conditions 
confounding the evaluation of knee OA, primary predominant 
patella-femoral disease, history of trauma/surgery in the 
affected knee, the coexisting disease that could preclude the 
completion of the trial Number of Patients: 120 (110 
completed the full follow-up) Study Design: RCT (randomized 
placebo-controlled)  
NR-INF-02, GS, NR-INF-
02+GS, or Placebo for 42 d. 
Placebo 400 mg twice daily 
or NR-INF-02 500 mg twice 
daily or GS 750 mg twice 
daily alone or combination 
of NR-INF-02 and GS. 
Patients are not suggested 
to take other medication 
except for acetaminophen 
as a rescue medication 
Outcome: VAS, WOMAC, CGIC, 
clinical assessment (joint 
tenderness, crepitation, effusion; 
terminal limitation of joint 
movement) at days 21 and 42 
Adverse effects were found in all 
four groups. GS regimes had 
more adverse events than the 
other groups.  
Srivastava, et 
al. (2016) 
Age Range: 40-80 y (mean age 50.2 and 50.3 y in CL extract and 
control groups respectively) Inclusion Criteria: Primary knee OA 
patients (40-80 y)  Exclusion Criteria: Less than 40 y or more 
than 80 y of age; patients who suffered from RA, DM, renal 
insufficiency, hepatic disease, cardiovascular disease, gout, or 
another ystematic disease; pregnant women Number of 
Patients: 160 (133 completed full follow-up) Study Design: RCT 
(two-arm double-blind, placebo-controlled parallel group) 
CL extract or placebo for 
four months. CL extract 500 
mg twice daily; placebo 500 
mg capsule+diclofenac 50 
mg/day twice daily.  
 
Outcome: VAS, WOMAC, 
biomarkers parameter (IL-1β, 
ROS, MDA) at day 0, 60, and 120 
Adverse effects were found in 
both groups; gastrointestinal 
problems, such as dyspepsia, 





Age Range: 38-80 y (30 subjects were 65-74 y) Inclusion Criteria: 
Patients with the history of knee pain with three of the following 
criteria: over 38 y old, less than 30 min of joint morning stiffness, 
crepitus on active motion, bony tenderness, bony enlargement, no 
palpable warmth of synovium would diagnose of OA Exclusion 
Criteria: Patients who were diagnosed with inflammatory arthritis 
(RA, gout, CPPD); patients who have the contraindication of using 
NSAID, history of peptic or gastric ulcer, renal insufficiency 
Number of Patients: 88 (75 completed full follow-up) Study 
Design: RCT (double-blind prospective RCT) 
Curcuminoid capsules or 
placebo for three months. 
Placebo twice 
daily+diclofenac 25 mg 
three times daily; 
Curcuminoid capsules 250 
mg twice daily+diclofenac 
25 mg three times daily.  
Outcome: VAS, KOOS (symptom, 
pain, function in daily living, 
function in sport and recreation, 
knee-related quality of life) 
 
Table 2: Risk of bias assessment 
  Domain of bias Authors’ 
assessment 
Support for assessment 
Madhu, Chanda, 
and Saji (2013) 
Random Sequence Generation 
(Selection Bias)  




Low Risk Both treatments had a similar appearance, prepared in "unique integer 
random numbers box containing either placebo or NR-INF-02 or 
combination" which both were given twice daily 
Blinding of Participants and 
Personnel (Performance Bias) 
Unclear Single-blinded study  
Blinding of Outcome 
Assessments (Detection Bias) 
Low Risk Not mentioned whether the outcome was measured blindly or not 
 
Incomplete Outcome Data 
(Attrition Bias) 
Low Risk  High dropout numbers from all groups due to lost to follow-up, hence 
adequate sample size of 35 per group was not achieved 
Selective Reporting (Reporting Bias) Unclear Not mentioned whether all outcomes are reported 
Other Bias  High Risk There was a disparity in the frequency of daily interventions between groups 
Srivastava et al. 
(2016) 
Random Sequence Generation 
(Selection Bias)  
Low Risk Computer-generated randomization was used 
Allocation Concealment 
(Selection Bias) 
Unclear Not mentioned 
Blinding of Participants and 
Personnel (Performance Bias) 
Low Risk Double-blinded study  
Blinding of Outcome 
Assessments (Detection Bias) 
Unclear Not mentioned  
Incomplete Outcome Data 
(Attrition Bias) 
Unclear Not mentioned 
Selective Reporting (Reporting 
Bias) 
Low Risk Although no strict reporting protocol was available, all expected 
outcomes of interest were reported 
Other Bias  Unclear Not mentioned 
Pinsornsak and 
Niempoog (2012) 
Random Sequence Generation 
(Selection Bias)  
Unclear Not mentioned whether computerized randomization was used 
Allocation Concealment 
(Selection Bias) 
Low risk Both treatments had a similar appearance; the placebo is identical to 
the curcuminoid capsule 
Blinding of Participants and 
Personnel (Performance Bias) 
Low Risk Double-blinded study  
Blinding of Outcome 
Assessments (Detection Bias) 
Unclear Not mentioned whether the outcome was measured blindly 
Incomplete Outcome Data 
(Attrition Bias) 
Low risk High dropouts due to loss to follow-up and adverse events (control: 
renal dysfunction and allergy; intervention: hair loss)  
Selective Reporting (Reporting 
Bias) 
Low Risk Although no strict reporting protocol was available, all expected 
outcomes were reported 
Other Bias  Unclear No evidence of bias from other sources 
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Fig. 2: Changes in VAS scores from baseline to post-treatment in intervention and control group 
 
Risk of bias in selected studies 
As mentioned above, the risk of bias assessment was conducted 
according to The Cochrane Collaboration’s tool for assessing the risk 
of bias in randomized trials [14]. The collective judgments of the 
present study’s authors are shown in table 2. 
Outcome: changes in VAS and WOMAC 
As the primary outcome, the data regarding changes in VAS and 
WOMAC were extracted from the selected studies. Synthesized data 
from the selected studies is represented in fig. 2. 
In Madhu et al.’s study, [7] VAS scores decreased from a mean value 
of 66.50 to 19.48 in the intervention group (CL extract) with p<0.05, 
while the control group (placebo) only decreased from a mean value 
of 61.50 to 46.03, and the other control group (glucosamine [GS] as 
standard treatment) decreased from a mean value of 60.97 to 29.29 
while the combination group (CL extract+GS) decreased from a 
mean value of 65.83 to 36.33.  
In Srivastava et al.’s study,[8] there was a decrease in VAS scores, from 
a mean value of 7.94 to 4.03 in the intervention group (CL extract) 
with p = 0.0001, while the control group (placebo+diclofenac) 
decreased within a shorter range, from 7.66 to 5.11. In other hand, 
Pinsornsak et al.’study10 found that the VAS score decreased from a 
mean value of 5.50 to 3.19 in the intervention group 
(curcuminoid+diclofenac) with p<0.001), while the control group 
(placebo+diclofenac) decreased from a mean value of 5.31 to 3.55. 
 
 
Fig. 3: WOMAC scores from baseline to post-treatment in intervention and control groups 
 
Madhu et al. [7] found the WOMAC score decreased from a mean 
value of 54.97 to 27.14 in the intervention group (p<0.05) while in 
the control (placebo) group, the score decreased from a mean value 
of 57.23 to 47.90, the other control group (GS as standard 
treatment) decreased from a mean value of 58.30 to 34.92, and the 
combination group (CL extract+GS) decreased from a mean value of 
60.73 to 36.21. Srivastava et al.[8] found the WOMAC score that 
evaluates pain decreased from a mean value of 15.10 to 9.48 in the 
intervention group (p = 0.06), while the control group decreased 
from a mean value of 15.29 to 10.16. The WOMAC score that 
evaluates stiffness decreased from a mean value of 5.55 to 4.08 in 
the intervention group (p = 0.73), while the control group decreased 
from a mean value of 5.31 to 4.16. The WOMAC score that evaluates 
function decreased from a mean value of 54.03 to 32.14 in the 
intervention group (p = 0.008), while its control decreased from a 
mean value of 50.99 to 33.88.  
Outcome: safety of treatment 
Side effects mentioned in the selected studies were collected to 
analyze the treatment’s safety. Severe adverse effects were not 
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found in the three selected studies, and adverse effects mainly 
affected the gastrointestinal system. Madhu et al. [7] reported a total 
of 13 adverse effects, observed across all four groups. Subjects 
treated with CL extract exhibited the fewest number of events 
during the intervention period, while subjects who received GS 
exhibited the largest number of events. The adverse effects 
mentioned in all groups were mild and did not warrant the 
withdrawal of any study medication. The adverse events mentioned 
in Madhu et al.’s [7] study were generalized body pain, cough, 
dyspepsia, fever, sore throat, and pedal edema. Srivastava et al. [8] 
reported a total of six adverse effects, observed in both the 
intervention and control groups. Subjects who received the placebo 
reported more adverse events than subjects who received CL 
extract. The adverse events mentioned in Srivastava et al.’s study 
were dyspepsia, nausea/vomiting, and constipation. There were no 
side effects mentioned in Pinsornsak et al. [10]. 
DISCUSSION 
Summary of evidence 
The primary outcome of interest in this study is to identify 
improvements in the WOMAC and VAS scores from baseline to post-
treatment in both the intervention and control groups. Two studies 
evaluated both WOMAC and VAS scores [7, 8], and one study 
evaluated only the VAS scores [10]. In all three trials, we found 
evidence that patients’ pain decreased, as shown by the 
improvements in scores. 
The VAS is an instrument designed to identify the characteristics of 
disease-related symptoms in individual patients. VAS is used to 
achieve rapid classification based on symptom severity. VAS has 
been widely used to measure pain intensity; it has also been used in 
a diverse population, including those with chronic diseases like OA 
[15, 16]. VAS is scaled from 0-10 with 0 described as no pain and 10 
as the worst imaginable pain [16]. 
The Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) is a questionnaire used to assess the health status 
of OA patients. WOMAC evaluates various aspects, including the 
patient’s health and function. This questionnaire consists of 33 
clinical symptoms (5 items), joint stiffness severity (2 items), pain 
severity (9 items), and daily life activity (17 items). Each item has 
five subscales where the best situation is described as “never” or 
“none” and the worst situation as “extreme” or “always”. In this type 
of questionnaire, lesser scores represent a better situation (less 
pain) [17]. 
In the study by Madhu et al., [7] there was a significant reduction in 
VAS scores: from 66.50±21.06 at baseline to 19.48±17.84 in the 
intervention group (CL extract) after 42 d of observation, with a 
p<0.01. There was also a significant reduction in VAS scores 
compared to placebo (61.50±13.71 at baseline to 46.03±20.84) and 
the combination of GS and CL treatment (65.83±15.48 at baseline to 
36.33±28.99), with a p<0.05. Nonetheless, no significant difference 
was found between CL extract and GS treatment alone.  
Unexpectedly, the effect of CL extract alone is superior compared to 
its combination with GS. Though unexplained, there may have been 
drug interactions that inhibited the combination therapy’s efficacy. 
Srivastava et al. [8] identified improvements in the VAS score, from 
7.94±0.13 at baseline to 4.03±0.08 after 120 d of treatment with CL, 
with a p<0.05 compared to its controls (placebo 7.66±0.14 at 
baseline to 5.11±0.14).  
In Pinsornsak et al.[10], both control (placebo) and CL extract-
treated samples of the treatment were given diclofenac (NSAIDs). 
The VAS score fell from the mean of 5.50 at baseline to 3.19 after 
three months of observation in the group of samples that received 
CL extract and diclofenac, with a p<0.001. Reduction of scores was 
greater in the group that received both treatments (CL extract and 
diclofenac), yet when compared with the second group (5.31 at 
baseline to 3.55 at post-treatment), the distinction was not 
statistically significant.  
Similarly, statistically significant improvements of WOMAC from 
baseline until post-treatment scores were reported [7], where the 
WOMAC score decreased from 54.97±9.85 at baseline to 
27.14±16.13 after 42 d of observation with a p-value of<0.01 
compared to its controls with p<0.05 (placebo 57.23±9.63 at 
baseline to 52.23±9.63). However, as with the VAS scores, there was 
no significant difference between the CL extract group and the GS 
group regarding the standard medication for OA (58.30±12.73 at 
baseline to 34.92±19.48). In Srivastava et al. [8], the WOMAC score 
included variables such as pain (11.19±0.26 and 9.48±0.17), 
stiffness (4.51±0.21 and 4.08±0.17), and PF (41.28±0.51 and 
32.14±0.40) were also significantly (p<0.05) reduced in the 
treatment group than placebo group at day 60 and 120, if compared 
to the baseline. 
It is worth mentioning a significant difference in improvement 
between the usage of CL extract in the studies by Srivastava et al. [8] 
and Pinsornsak et al. [10] Based on Perkins et al.,18 an increased dose 
of CL extract could improve the generalizability of results. Thus, the 
usage of 500 mg CL extract compared to 250 mg CL extract affects the 
overall improvement of VAS scores in patients with OA [18]. 
Madhu et al. [7] also assessed the use of acetaminophen 
(paracetamol) tablets in a dose range of 2,000 to 4,000 mg/day as 
rescue medication; this finding was reported as a secondary 
outcome measure, which was significantly less in the CL extract 
group compared to other groups (p<0.01).  
Madhu et al. [7] also studied the Clinician Global Impression of 
change (CGIC) to assess improvement in patients’ overall condition 
and evaluate the therapeutic efficacy. It is shown from his that there 
was a significant improvement in patients treated with CL extract. 
This effect may be considered as an additional parameter that 
supports CL extract’s therapeutic efficacy [7]. 
In another study conducted by Pinsornsak et al. [10], using the Knee 
Injury and Osteoarthritis Outcome Score (KOOS) to evaluate short-
and long-term symptoms and function of patients with a knee injury 
and OA, there was an improvement in all five aspects. The 
experimental group showed a superior or equal improvement at the 
end of the study, especially regarding pain and function in daily life. 
However, the control group had no statistically significant 
improvement (p>0.05) compared to the beginning of the study [10]. 
It is mentioned that there is a significantly raised level of Radical 
Oxygen Species (ROS) and Malondialdehyde (MDA) in patients with 
OA. The study by and Srivastava et al. [8] found that treatment with 
CL extract brought a decrease in baseline value of IL-1b, ROS, and 
MDA after two months of treatment. This decrease was further 
reduced as the treatment was continued up to four months. 
Therefore, this study found that CL extract can reduce biomarkers of 
inflammation [
Despite the evidence of overall improvement, as scored with VAS, 
WOMAC, CGIC, KOOS, it is known that radiological features correlate 
poorly with pain relief in OA. Madhu et al. [7] and Srivastava et al. 
[8] mention that the radiographic appearance of the joints was not 
improved, even after four months of treatment.  
8]. 
Limitations  
This review is limited primarily by the scales used as the main 
outcome interest in the studies, which are both relatively subjective 
according to the patients’ perspective of their pain. Another common 
limitation shown in these studies is a generally low sample size due 
to dropout during the follow-up process. Pinsornsak et al. [10] noted 
the limitation of an inadequate dose of curcumin given to subject 
groups since there were no previous studies evaluating the most 
effective regimen of CL extract in the treatment of OA in humans. 
Madhu et al. [7] reported an insufficient treatment duration, causing 
the inability to assess safety and efficacy for long-term management. 
Future research should focus on evaluating the effective treatment 
dosage of CL-extract in OA patients, from the perspectives of both 
efficacy and adverse events. 
CONCLUSION  
This review provides evidence that CL extract is beneficial as an 
alternative medication for OA treatment, shown by the reduce 
scores of VAS and WOMAC in all studies we reviewed. Adverse 
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effects occurred only in a few patients taking CL extract, with no 
serious adverse effect. We suggest the use of CL extract as an option 
of herbal treatment for OA. 
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